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Differentiation of progenitors in the liver:  
a matter of local choice
Luke Boulter, Wei-Yu Lu, and Stuart J. Forbes
Medical Research Council Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
The liver is a complex organ that requires multiple rounds of cell fate decision for development and homeostasis 
throughout the lifetime. During the earliest phases of organogenesis, the liver acquires a separate lineage from 
the pancreas and the intestine, and subsequently, the liver bud must appropriately differentiate to form metabolic 
hepatocytes and cholangiocytes for proper hepatic physiology. In addition, throughout life, the liver is bombarded 
with chemical and pathological insults, which require the activation and correct differentiation of adult progenitor 
cells. This Review seeks to provide an overview of the complex signaling relationships that allow these tightly reg-
ulated processes to occur.
Introduction
Progenitor cells have highly regulated mechanisms govern-
ing proliferation and differentiation to achieve accurate tissue 
repair. In several organ systems, the hierarchy of stem cells, tran-
sit amplifying-progenitor cells, and differentiated mature cells 
is well described, including the signaling pathways that define 
these stages (1–4), though much remains to be characterized for 
this hierarchy in liver. The adult liver has an impressive regener-
ative capability, and classical experiments in rats following par-
tial hepatectomy demonstrated that the liver can regrow to its 
original size within ten days. This capability is utilized in clini-
cal scenarios in which partial hepatectomy is used to resect liver 
tumors, and in living donor transplantation in which a portion 
of the liver is taken from a donor and transplanted into a recipi-
ent, with both remnants regrowing into a functional liver mass. 
This regeneration occurs through division of the mature epithe-
lial cells (hepatocytes and cholangiocytes) within the liver, which 
leave their normal mitotically quiescent state, termed G0, and 
enter cell cycle and mitosis.
During chronic liver injury this normally efficient renewal from 
mature epithelial cells becomes impaired. In many liver diseases, 
such as chronic viral hepatitis (5) and non-alcoholic fatty liver dis-
ease (6), hepatocytes become senescent and unable to efficiently 
regenerate the parenchyma. In this scenario, hepatic progenitor 
cells (HPCs) become activated and are sufficient to regenerate the 
biliary and hepatocellular epithelium (7, 8). The biology of HPCs is 
less studied in comparison to analogous progenitor cells in other 
adult tissues, and markers that delineate the stem versus transit 
amplifying populations are not clearly defined (9–11).
While the putative adult liver stem cell is often thought to reside 
within the canals of Hering, located at the terminal branches 
of the biliary tree, multiple lines of recent work suggest that a 
label-retaining stem cell might exist throughout the biliary net-
work (12, 13) and even in the common bile duct (14, 15). One 
model posits that these putative stem cells may be differentially 
activated in diverse disease patterns and may have different differ-
entiation potencies depending on their location, though this idea 
has not yet been formally addressed. What is known is that this 
putative stem cell gives rise to a transit-amplifying population of 
HPCs. Mechanisms of HPCs have been increasingly studied, and 
a broad class of factors that can activate the proliferation of HPCs 
has been identified (16, 17). To restore function to the damaged 
liver, these bipotential HPCs must differentiate into hepatocytes, 
the key metabolic cells of the liver, and cholangiocytes, which line 
the biliary tree and transport bile into the intestine. The mech-
anism by which HPCs differentiate into these two key epithelial 
types is poorly defined, but recent advances in transgenic mouse 
technology and the ability to manipulate HPCs in vitro and in vivo 
has shown that the fate of HPCs depends not only upon which sig-
naling cascades are activated within the HPCs, but also the disease 
context in which HPCs evolve.
Expansion of HPCs is a multifactorial process
HPCs are facultative and not activated in healthy liver. The induc-
tion of HPC proliferation is critical to generate sufficient numbers 
of transit-amplifying cells, which can subsequently differentiate 
into the mature hepatic epithelia. Multiple signaling pathways 
have been identified as mitogenic for HPCs (for a comprehensive 
review, see ref. 18). TGF-β is a potent mitogen associated with the 
inflammatory response that is able to act differentially on TGF-
βR2 expressed by hepatocytes and HPCs through variable glyco-
sylation of the TGF-β receptor (19). Hepatocyte proliferation is 
restricted by TGF-β, although HPCs with glycosylated TGF-βR are 
not repressed by TGF-β and can proliferate in an inflammatory 
environment. TNF-like weak inhibitor of apoptosis (TWEAK) acts 
though its receptor, Fn14, activating NF-κB signaling and potently 
inducing HPC proliferation. Knockout of either the TWEAK 
ligand or the Fn14 receptor results in a severely abrogated HPC 
response; moreover, exogenous injection of TWEAK is sufficient 
to induce HPCs in an undamaged mouse liver (16, 17).
In vitro assessment of the stemness and differentiation 
capacity of HPCs
Due to limitations in the available lineage-tracking system in the 
adult liver, much of our understanding of HPC differentiation has 
largely been defined in vitro. HPCs are isolated, and their ability 
to form clones (clonogenicity) and to differentiate into multiple 
lineages (multipotentiality) can be assayed.
Wang et al. sought to identify a bipotential population of cells 
with self-renewing capacity that were transplantable and could 
contribute to hepatic parenchyma in vivo (20). c-kit–positive 
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progenitor cells were isolated from wild-type donors and trans-
planted into fumaryl acetoacetate hydrolase–null (Fah–/–) recipi-
ent mice, in which hepatocytes lack a tyrosine metabolic pathway 
(20). The c-kit–positive cells differentiated into genetically normal 
hepatocytes, which proliferated to rescue the Fah–/– phenotype (20). 
In later studies this group generated a suite of antibodies against 
HPCs, such as MIC1-1C3 and OC-2, which were used to identify a 
population of putative HPCs (21). However, a number of the anti-
bodies generated in these studies also cross-react with bile ducts in 
the healthy adult mouse, and as such these markers may not isolate 
a pure HPC population. This problem was addressed by culturing 
sorted cell populations in vitro at clonal density using selection 
based on the expression pattern CD45–CD11b–CD31–MIC1-1C3+C-
D133+CD26; these cells were bipotent, with the capacity to differ-
entiate into two distinct cell types, hepatocytes and cholangiocytes 
(22). Furthermore, additional data suggested that a liver-regenerat-
ing cell resides within the epithelial cell adhesion molecule–positive 
(EpCAM-positive) population within the uninjured adult liver, and 
that these cells are capable of forming epithelial colonies with bi-
lineage potential (23). However, the identity of these cells within 
the EpCAM-positive pool remains enigmatic.
Lineage tracing in the adult liver
The contribution of progenitors to tissue turnover and regen-
eration is difficult to address in adult organs, which are already 
structured and contain terminally differentiated cells. To this end, 
several stem cell lineage–tracing tools have been developed to assess 
the location of HPCs and the mechanisms governing their contri-
bution to regeneration. The basic principle of lineage-tracing ani-
mals is that the putative stem or progenitor cell is indelibly marked; 
as such, any progeny arising from this cell will also carry the same 
distinct mark. The most common method of lineage tracing is to 
use an inducible, lineage-specific Cre-recombinase crossed with a 
mouse that harbors a flox-stop-flox reporter (such as GFP or LacZ). 
Following induction, Cre recombinase excises the stop codon and 
the stem cell is subsequently labeled irreversibly with either GFP or 
LacZ. Therefore, its progeny can be tracked during tissue homeo-
stasis and regeneration (24).
The initial liver studies from Linda Greenbaum and colleagues 
identified Foxl1 as a marker of adult HPCs (25). This was an 
important advance because previous attempts to track cells in the 
adult liver had been limited primarily to markers of adult HPCs, 
including the cytokeratins Krt7 and Krt19 and other liver-re-
stricted markers (e.g., α-fetoprotein) expressed on fetal hepato-
blasts, and, as such, made adult analysis of these tissues impos-
sible (26, 27). The use of Foxl1Cre flox-stop-flox LacZ reporter mice 
demonstrated that HPCs could contribute to mature hepatocytes 
when livers were damaged and progenitor cells were activated, 
but the number of positive hepatocytes was rare (0.5% Foxl1 and 
hepatic nuclear factor 4α [HNF4α] dual-positive hepatocytes) and 
likely too low for mechanistic studies.
The use of inducible Cre provides an attractive alternative to con-
stitutive reporter systems. In this context the Cre recombinase 
is fused to an estrogen response element, which upon adminis-
tration of 4-hydroxytamoxifen results in the translocation of the 
fusion protein to the nucleus, where the enzyme can then induce 
recombination (28). Administration of an inducing agent means 
labeling of HPCs can be strictly timed, and the cellular progeny 
that result from this recombination can be tracked over time. Uti-
lizing this inducible Cre technology under the control of the Sox9 
transcriptional control elements, Furuyama et al. described how 
Sox9 is expressed in HPCs and biliary epithelium in the regener-
ating liver (29). Using both an inducible Sox9-Cre/LacZ mouse and 
also a Sox9-GFP reporter mouse in which GFP is expressed in Sox9-
expressing cells, the authors found Sox9+ cells in close proximity to 
the biliary tree in normal liver. Interestingly, when healthy animals 
were left for up to 12 months, the parenchyma of these animals 
was replaced by cells of a Sox9 origin, the putative HPCs (29). This 
result was remarkable and challenged the dogma about normal 
homeostatic mechanisms in the liver — rather than the mature 
Figure 1
Liver development involves multiple phases of specification and differentiation. (A) During liver development, the liver bud is specified from the 
remainder of the endoderm by Wnt expression from the cardiac mesoderm. HSC, hepatic stellate cell. (B) Once specified, the endoderm matures 
into fetal hepatoblasts that are capable of bilineage differentiation into hepatocytes and cholangiocytes. (C) Spatial heterogeneity across the 
developing liver results in the specification of the ductal plate though activation of the Notch signaling pathway, in close proximity to what will 
ultimately become the portal tract. (D) Once specified, the ductal plate is patterned, and the side adjacent to the portal mesenchyme closely 
associates with laminin and expresses high levels of Sox9, whereas the side adjacent to the developing parenchyma expresses TGF-β–mediated 
C/EBP and contributes to zone-1 hepatocytes.
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parenchyma being responsible for maintaining itself, turnover 
of the healthy liver was progenitor mediated. Furthermore, when 
Sox9-Cre/LacZ mice were injured there was a startling expansion 
of Sox9-positive progeny that quickly restored normal epithelial 
function (29). However, in 2011 a second paper investigating the 
embryonic origin of HPCs shed some light on these exceptional 
Sox9 results (30).
Work from Frédéric Lemaigre’s group clearly demonstrated that 
the Sox9-positive bile duct and progenitor cell are deposited from 
the ductal plate during hepatic ontogeny; in a thorough study the 
authors demonstrated that the embryonic ductal plate gives rise 
not only to biliary epithelium, as previously expected, but also to 
HPCs and to a subpopulation of hepatocytes in periportal zone 1 
of the adult liver (30). Moreover, upon tamoxifen administration 
to adult Sox9 reporter mice, the zone 1 hepatocytes upregulated 
Sox9. This control suggests that the Sox9-positive cells identified 
by Furuyama et al. (29) may in fact be periportal hepatocytes that 
upregulate Sox9 and activate the transgene in response to tamox-
ifen administration.
The work from Uemoto and Furuyama (29), however, is not 
without considerable merit because this paper clearly demon-
strates a streaming gradient of cells that arise at the portal tract 
and then divide and potentially migrate through the zones of 
the liver until they reach the central vein. This confirms the 
so-called “streaming liver hypothesis” originally described by 
Zajicek and colleagues (31, 32).
The culmination of these lineage-tracing strategies has resulted 
in an important recently published work by the Leclercq group 
(7). Using osteopontin-1 as a marker, the authors demonstrate 
that HPCs express osteopontin (a glycoprotein that marks HPCs), 
emerge from bile duct, and are capable of directly differentiating 
into hepatocytes (7). Importantly, HPCs regenerated hepatocytes 
following chronic hepatocyte injury (2.4% of hepatocytes were 
positive for GFP after two weeks of a choline-deficient, ethionine-
supplemented [CDE] diet), but not following biliary injury and 
regeneration (3,5-diethoxycarbonyl-1,4-dihydrocollidine diet, with 
which 0% YFP-positive hepatocytes were seen), demonstrating that 
the HPC microenvironment is critical for HPC expansion and dif-
ferentiation, as we have previously suggested (33). Interestingly, 
the HPCs radiated from their niche to the site of injury but con-
tributed little to hepatocyte regeneration during the injury on the 
CDE diet. However, during recovery with a normal diet, HPCs dif-
ferentiated into mature, replication-competent hepatocytes that 
could then maintain parenchymal regeneration themselves. This 
insight has relevance to the study of human liver disease, which 
may have intermittent relapsing-remitting disease activity.
There has been debate in the liver field as to whether hepatic stel-
late cells are capable of undergoing mesenchymal-epithelial tran-
sition (MET), thereby contributing to parenchymal regeneration. 
Work from Yang and colleagues utilized a constitutive GFAP-Cre 
line, which labeled the biliary tree and hepatic stellate cells (34). 
This study demonstrated for the first time that GFAP-expressing 
Figure 2
HPCs are involved in a complex microenvi-
ronment and are subject to multiple signals. 
Regeneration in the liver can be broadly 
characterized into hepatocellular or biliary 
regeneration. In the former context, progenitor 
cells irradiate from the portal tracts, in which 
they are sheathed in laminin, which facilitates 
their expansion. Upon exit from the laminin 
niche, these cells are subject to differentiation 
cues, such as Wnt and HGF, which activate 
the pro-hepatocyte transcriptional cascade in 
HPCs. In biliary regeneration, HPCs emerge 
in a similar fashion, but they remain in the 
laminin ECM, in which fibroblasts are able to 
influence their maturation though activation 
of the Notch signaling pathway. This pathway 
influences the activation of the HNF6/HNF1β 
transcriptional network to correctly specify 
cholangiocytes.
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cells could be traced into hepatocytes, and by analyzing the kinetics 
of disease recovery, Yang et al. concluded that the parenchyma can 
be regenerated from non-epithelial, GFAP+ cells (34). However, the 
use of a constitutive GFAP-Cre expression system does not fully 
exclude the possibility that GFP-labeled hepatocytes are derived 
from GFAP-expressing bile ducts. This observation, however, offers 
a tantalizing suggestion that stellate cells may have a progenitor 
role in the adult liver; this has been investigated by other groups in 
the liver (35, 36) and other tissues (37). Of course stellate cells are 
also subject to regional signaling in the liver, and multiple develop-
mental regulators, including Necdin-Wnt (38–40) and Hedgehog, 
have been implicated in the differentiation of hepatic stellate cells 
into fibroblasts, the latter of which control cellular metabolism 
to regulate fate (41). Intriguingly, differentiation of these fibrob-
lasts is in part mediated through epigenetic regulation of PPARγ 
(42–44), although there is little evidence to indicate which signals 
might facilitate MET.
Do these murine studies shed any light on the human condi-
tion? Alison and colleagues have harnessed the inability of the 
cell to repair mutations in mitochondrial DNA to ask whether 
human livers have such progenitors (8, 45). By identifying cells 
in which the mitochondria have a COX mutation, this group 
described patches of epithelium in the liver in which the mito-
chondria were mutated, and when random, discrete regions of 
the patch were analyzed the mitochondrial mutation was con-
sistent across the sample. This result suggests that the COX 
mutation carried in these mitochondria arose from a common 
ancestor of cells throughout the patch. Of course, this does not 
necessarily point to a progenitor cell, but if both hepatocytes and 
cholangiocytes could be identified with the same mitochondrial 
mutation, then this would be compelling evidence that in the 
adult human liver both key epithelial types can originate from a 
common precursor.
Inspiration from development: liver patterning during 
ontogeny
During development, embryonic progenitors (hepatoblasts) 
must make lineage decisions similar to adult HPCs and form 
the biliary tree and hepatocytes. Once the liver bud has formed 
from the primitive endoderm, epithelial lineage separation 
occurs; a population of hepatoblasts adjacent to the portal 
mesenchyme is specified and forms the ductal plate (46). This 
process requires the differentiation of hepatoblasts into the bile 
ducts and repression of the ductal phenotype in the developing 
hepatocytes (47–49), summarized in Figure 1. The delineation of 
bile duct from the rest of the parenchyma occurs early in devel-
opment and is initiated by asymmetry of the ductal plate where, 
in E-cadherin–positive cells, HNF4α and Sox9 are asymmetrically 
expressed on the parenchymal and the portal faces, respectively. 
This asymmetry of the ductal plate is enhanced through deposi-
tion of laminin on the portal side of the presumptive bile duct, 
whereas the repression of biliary phenotype in the parenchymal 
side of the ductal plate is driven through TGF-β signaling, puta-
tively through the TGF-βR2 (47). This regulatory asymmetry is 
critical, though not for the propagation of a biliary phenotype. 
As in Sox9 knockout livers, there is little change in the expression 
of HNF1β, HNF6, and hematopoietically expressed homeobox 
(HEX), but rather there is a failure of hepatocyte fate repression. 
Without Sox9 repression of C/EBPα, there is a failure to resolve 
the ductal plate during embryogenesis.
A critical parameter for lineage specification of the adult biliary 
system is the Notch signaling pathway (50). During development, 
this signaling cascade is critically implicated in the formation 
of cholangiocytes and also in the maturation and terminal pat-
terning of the biliary tree in a multitude of species (51–53). In the 
normally developing liver, Notch2 is activated in the presumptive 
cholangiocytes by jagged 1, which is expressed by the portal mes-
enchyme (54). In this context, an HNF6/HNF1β signaling cascade 
is activated as a direct result of Notch intracellular domain inter-
actions with the promotor of HNF6 (55, 56). Loss of Notch sig-
naling in biliary development in mice, through genetic ablation of 
jagged 1 or haplosufficiency of Notch2, results in a reduction in 
biliary development and failure to pattern the biliary tree (57–60). 
The human congenital disease Alagille syndrome, which is caused 
by mutations in Notch pathway components, is characterized by 
a biliary paucity with failure to correctly resolve the ductal plate 
during development; this phenotype can also be observed in adult 
mice that harbor a fringe mutant in which Notch is inappropri-
ately activated (61). Huppert and colleagues demonstrated that 
the Notch1 intracellular domain must act in a dose-dependent 
fashion, showing that overexpression of the Notch1 intracellular 
region during development results in a hyper-arborized biliary net-
work, presumably at the cost of mature parenchyma (62).
Whereas the role for Notch in development is highly stereotyped, 
and its effect is common between species, the role for Wnt/β-cat-
enin signaling in the developing liver is confounded and complex. 
Wnt plays critical roles not only in expansion of the liver bud 
(63–65), but also in formation of the definitive hepatoblasts (66), 
biliary proliferation (67), and hepatocyte maturation (68, 69). As 
such, elucidating the temporal and spatial action of the canonical 
Wnt pathway is complex.
Initial transgenic studies that looked at activating the Wnt/ 
β-catenin signaling pathway through embryonic loss of adenoma-
tosis polyposis coli (APC), a critical regulator of β-catenin stabil-
ity, demonstrated that this signaling cascade was required for the 
expansion of fetal hepatoblasts (66). Furthermore, the presence of 
constitutively activated β-catenin resulted in hypotrophy of the 
developing liver with perturbed hepatoblast differentiation occur-
ring at embryonic day E11.5 and resulted in late lethality in utero 
at E16.5–E18.5 (66). These data, however, are in contrast to data 
from the Monga group (70). Tan et al. demonstrated that embry-
onic deletion of the gene encoding β-catenin under the control 
of the FoxA3-Cre transgene (expressed by E9.5) results in a failure 
of liver development through reduced hepatocyte differentia-
tion, increased hepatoblast apoptosis, and reduced hepatoblast 
proliferation (70). The phenotype in the embryos is only realized 
at E12, a timing that is similar to APC mutant embryos. These 
data together indicate not only that Wnt signaling is critical for 
fetal hepatogenesis, but also that in normal development, modu-
lation of this pathway must be exquisitely timed for correct liver 
development. Interestingly, in the postnatal liver, activation of the 
canonical Wnt signaling pathway is required for the expansion of 
hepatocytes and is responsible for expansion of the liver. Selective 
postnatal loss of β-catenin results in a reduced organ size, and as 
such suggests a conserved functional outcome of these signaling 
pathways during development and maturation (71). Intriguingly, 
targets of β-catenin such as lymphoid enhancer binding factor 1 
and Myc are directly responsible (in association with liver-enriched 
transcription factors) for patterning the developing liver and are 
critical for correct metabolic zonation (68).
review series
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 5   May 2013 1871
Mechanisms of differentiation during adult regeneration
Whereas the mechanisms of lineage specification during hepatic 
ontogeny are increasingly understood, the cues by which HPCs 
in the adult liver are specified into different lineages are not well 
described in situ. However a handful of studies have looked at the 
mechanism by which HPCs differentiate in vivo. The HGF receptor 
c-Met is required for the maturation of HPCs into hepatocytes, and 
until recently this was all that was known about the potential mech-
anisms by which HPCs become hepatocytes (72). More recently, lin-
eage-tracing evidence has emerged demonstrating that inhibition of 
laminin signaling with iloprost, a synthetic analog of prostacyclin 
PGI2, in HPCs during regeneration results in the precocious differ-
entiation of HPCs into hepatocytes (7), reiterating previous descrip-
tive work examining laminin in the HPC response (73, 74).
We have identified a re-establishment of the embryonic state 
in regeneration; Notch and Wnt are required for HPC differenti-
ation, and their interaction is necessary for appropriate delinea-
tion of hepatocellular versus biliary fate (33). During activation of 
HPCs in biliary diseases of both mouse and human, HPCs express 
the receptors Notch1 or Notch2, respectively; these are activated 
though interaction with jagged 1. In the mouse, the periportal 
fibroblasts that surround the regenerating bile ducts express this 
ligand and appear to recapitulate in some regards the portal mes-
enchyme seen in development (33, 75).
This Notch-high state appears to delineate the default pathway 
for the development of HPCs into cholangiocytes, and critically 
this pathway is inhibited during regeneration of hepatocytes 
through the ubiquitin ligase Numb. In HPCs undergoing hepa-
tocyte differentiation, Numb transcription is activated by β-cat-
enin and as such represents a critical node at which the Notch 
and Wnt pathways can interact to enable lineage specification. 
In recent years, macrophages have been described as a source of 
Wnt, often in cancer, though some regeneration studies have 
also described macrophage-derived Wnt (76, 77). Ablation of 
macrophages during hepatocyte regeneration removed the stim-
ulus for HPCs to become hepatocytes; instead, they differenti-
ated into cholangiocytes and formed biliary structures. These 
results have also been confirmed in independent studies in 
which macrophages have been depleted in the liver (78). Notably, 
phagocytosis of the hepatocyte debris promoted profound Wnt 
upregulation in macrophages, providing a critical link between 
hepatocyte death and HPC fate that enables co-ordinated and 
appropriate tissue renewal. Furthermore, this model provides 
a mechanism linking local tissue injury and inflammation pat-
terns of specific diseases with the extra- and intracellular signal-
ing controls that govern HPC fate.
Clinically, in the context of severe liver injury accompanied by 
a failure of hepatocyte regeneration and consequent functional 
decrease in parenchymal mass, a marked ductal reaction occurs, 
which likely represents a regenerative response that is “too biliary” 
(79, 80). In such situations, promoting hepatocytic differentiation 
of progenitors may provide a legitimate future target for drugs 
and small molecules. Indeed, by genetically expressing stabilized 
Wnt in mouse liver progenitors, we have found that HPCs can be 
coaxed in vivo into a hepatocyte fate rather than a biliary fate (33).
Parallels in cancer
Recent intriguing work in mice suggests that the overactivation 
of the Notch signaling pathway (through ectopic expression of 
the Notch1 intracellular domain in hepatocytes in vivo) can 
transdifferentiate these mature cells into cancerous cholan-
giocytes (81, 82). This phenomenon obviously parallels the 
mechanisms of biliary development discussed earlier, in that 
repression of the hepatocyte phenotype and promotion of the 
biliary phenotype can specify cells toward a cholangiocyte phe-
notype. In these mouse models of cancer, Notch deregulation 
clearly results in the propagation of a naive phenotype that is 
carcinogenic. Similarly, Wnt deregulation has been implicated 
in the development of hepatocellular carcinoma (83). These 
cancers occur most commonly in the context of chronic liver 
injury and regeneration, and emerging evidence suggests that 
parallels in the signaling pathways linking development, regen-
eration, and cancer may enable new treatment modalities to 
promote healthy liver regeneration and inhibit the formation 
of liver cancer.
Conclusions and perspectives
Clearly the activation and evolution of HPCs during disease is 
one of multiple pathogenic phases analogous to disease onset 
in other adult tissues. In this model a resident (and yet to be 
identified) hepatic stem cell is activated, giving rise to a tran-
sit-amplifying pool known as HPCs. These cells then undergo 
rapid division and expansion, likely driven by inflammatory 
cues, principally TWEAK. These HPCs evolve in a laminin-rich 
microenvironment, which is necessary to facilitate their expan-
sion and maintain their naivete. In this steady state, once the 
niche is established, HPCs are subject to multiple classical sig-
naling cascades that are context (disease) dependent. If the HPCs 
are exposed to Notch signaling whilst in the niche, they form 
cholangiocytes and maintain a laminin rich basement mem-
brane around themselves. When HPCs exit the laminin sheath, 
these cells are exposed to multiple ligands from their local envi-
ronment, such as macrophage derived Wnt or HGF, which acts 
through c-Met expressed by HPCs and initiates the activation of 
a pro-hepatocyte signaling cascade and results in differentiation 
of HPCs into hepatocytes (Figure 2).
Regeneration in the liver is undoubtedly an important clinical 
target. The ability to influence HPCs to proliferate and to regulate 
their differentiation may ultimately lead to exciting new therapies 
for chronic liver diseases. Until recently, HPC research has moved 
slowly compared with research for other organ systems such as 
gut, blood, and skin. Difficulties identifying HPCs in vivo, limited 
tools available to identify their targets, and difficulties culturing 
highly pure populations capable of modeling the in vivo situation 
have been at least partly overcome, making the present a prime 
time for progress in this field.
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